The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients with Secondary Pulmonary Hypertension

Launched by FAYOUM UNIVERSITY · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how effective a combination of two medications—dapagliflozin and sildenafil—can be in treating patients with heart failure who also have a condition called secondary pulmonary hypertension, which affects blood flow in the lungs. The goal is to see if adding sildenafil to the treatment can improve symptoms better than using dapagliflozin alone. Researchers are currently looking for participants aged 65 to 74 who have been diagnosed with heart failure and experience symptoms like dizziness, heart palpitations, or shortness of breath.

To be eligible for the trial, patients must have a confirmed diagnosis of heart failure with secondary pulmonary hypertension. However, certain individuals will not qualify, such as those with severe allergies to the medications being tested, other serious heart conditions, or those who are pregnant or breastfeeding. Participants in the trial will receive treatment and be monitored for their health and any changes in their symptoms. This study offers an opportunity to contribute to research that could help improve treatment options for patients facing these challenging conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience:
• • Dizziness or fainting
• • Heart palpitations, which may feel like your heart fluttering or skipping beats
• • Shortness of breath
• Exclusion Criteria:
• • Patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications.
• • Individuals with contraindications to the use of sildenafil or dapagliflozin.
• • Patients with pulmonary arterial hypertension (PAH) due to conditions other than heart failure (e.g., idiopathic PAH).
• • severe hepatic impairment
• • aged less than 18 years.
• • valvular heart disease .
• • Patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures.
• • life expectancy of less than 6 months .
• • Pregnant or breastfeeding women